MOTS-c: uses, evidence and status | Inside Your Peptides

compound file

The answer, first. A sixteen-amino-acid peptide encoded inside mitochondrial 12S rRNA, identified in 2015 at the University of Southern California, and released by the body during exercise. The strongest evidence is for insulin sensitivity and blood glucose, graded D — animal or mechanism only.

MOTS-c prevented high-fat-diet and age-dependent insulin resistance in mice by inhibiting the folate cycle and activating AMPK in skeletal muscle ¹.

The first human trial, 120 adults with prediabetes, is recruiting ⁶. Every other use — fat loss and body weight, physical performance and age-related decline, longevity, circulating MOTS-c as a disease marker — grade D or E: animal or mechanism data with no controlled human outcome.

What it is used for

Every use graded on its own evidence, not the compound as a whole. 5 outcomes, ranked by what the human record supports.

#outcome · human · animal · gradewhat the best evidence actually shows

01Insulin sensitivity and blood glucoseone phase 2 recruiting, no results · mouse metabolic studiesgrade DMOTS-c prevented high-fat-diet and age-dependent insulin resistance in mice by inhibiting the folate cycle and activating AMPK in skeletal muscle ¹. The first human trial, 120 adults with prediabetes, is recruiting ⁶.

02Fat loss and body weightno completed trial · diet-induced obesity in micegrade DInjected MOTS-c prevented diet-induced obesity in mice fed a high-fat diet ¹. No completed human outcome trial exists. Community fat-loss reports nearly always describe a calorie deficit or a GLP-1 alongside it.

03Physical performance and age-related declinemeasured, never dosed · young, middle-aged and old micegrade DMOTS-c improved physical performance in 2-, 12- and 22-month-old mice, and treatment begun at 23.5 months raised late-life capacity ². In humans only the body's own MOTS-c was measured, after exercise ².

04Longevitygenetic association only · no lifespan trialgrade DA mitochondrial variant that alters MOTS-c, m.1382A>C, is more common in long-lived Japanese people ³. That is an association in a population, not a treatment result. No lifespan study has dosed MOTS-c.

05Circulating MOTS-c as a disease markercross-sectional cohorts · supportivegrade DBlood MOTS-c runs lower in obese children, in adults with coronary endothelial dysfunction, in obesity generally and in peritoneal dialysis patients ⁴⁵⁷¹⁰. Associations only. Low MOTS-c has not been shown to cause anything.

gradewhat it means

ARegulatory approval, or multiple adequately-powered trials agreeing with each other

BAt least one well-powered human randomised trial, with the direction replicated

CSmall or open-label human trials only

DAnimal or mechanism data only, with no controlled human outcome

EA claim the human trials have already killed

How it works

The proposed mechanism, in three steps. A mechanism is a reason to run a trial, never a substitute for one.

1targetMOTS-c is translated from a short open reading frame inside mitochondrial 12S rRNA and acts mainly on skeletal muscle ¹.

2signalIt inhibits the folate cycle and the de novo purine synthesis tethered to it, which activates AMPK ¹.

3effectUnder metabolic stress it moves into the nucleus and changes nuclear gene expression, including metabolic and antioxidant genes ⁸.

What it does not do

Claims the current record does not support. Worth knowing before you set expectations.

not supported by the evidence

MOTS-c burns fat in humans. No completed trial has measured fat mass on MOTS-c. The registered phase 2 measures insulin sensitivity, weight and waist and has posted no results ⁶.
MOTS-c builds muscle. No study in any species used muscle mass as an endpoint. The mouse work measured running performance, not tissue ².
It is an exercise mimetic, so it replaces training. Exercise raises the body's own MOTS-c ². That is the reverse of the claim, and no study has tested injected MOTS-c against training.
Safety is established. FDA states it has identified no human exposure data on MOTS-c drug products administered by any route ⁹.

How it is used

What published protocols administered, and what the community reports doing. Descriptive on both counts, and never a recommendation.

routeSubcutaneous injection. Some vendors sell an oral or intranasal form, and no published human work used either.

formatLyophilised powder in vials, reconstituted with bacteriostatic water.

published dosesNo human dose has been published. Mouse studies injected MOTS-c over weeks, and the late-life mouse study dosed three times a week ¹². The registered phase 2 measures the Matsuda index at 12 weeks and has posted neither its schedule nor a result ⁶.

human pharmacokineticsNo human pharmacokinetic data published.

reported conventionsAs reported on peptide and coaching forums, 2020-2026: a daily subcutaneous amount for five to ten days, followed by a long pause. Or a smaller amount several times a week, timed around training. Reports cluster on training days. Convention, not guidance.

commonly paired withSS-31 NAD+

This site does not publish protocols to follow. The doses above are what studies administered or what users report, stated as facts about the literature and the market. How protocols are structured, mixing and storage and the reconstitution calculator cover the arithmetic.

What to expect

Where a trial measured it, the trial. Where only the community reports it, that is said out loud.

onsetNo trial measured onset. As reported: training energy inside the first week is the most common early note, and null reports at five weeks sit in the same threads. Energy is a training input, not a body-composition outcome, and nothing in the literature times it.

most common reportAs reported: more workout output while in a calorie deficit. No change at all is the second most common report.

adverse effectsNo trial has published adverse event rates. As reported: injection site reactions and occasional flushing. FDA states it has identified no human exposure data for MOTS-c by any route, so there is no safety profile to quote ⁹.

the stop signalAs reported: people stop at the end of a fixed run rather than on a signal. No published stopping rule exists for this peptide.

Approval and status

What regulators and sport bodies have actually said, separately from what the evidence shows.

approvalNot approved anywhere. Sold as a research chemical.

FDAListed among bulk substances nominated for compounding then withdrawn. FDA states no human exposure data exists by any route.

sport [WADA]Not named on the List. Caught by S0, non-approved substances.

sold asresearch chemical

Covered in depth

These reports grade MOTS-c at length and carry their own verified reference lists.

Fullness Is Not Muscle: What Tesamorelin, CJC-1295 With Ipamorelin, and MOTS-c Actually Do to Body Composition

Three compounds, three different stories, and one measurement problem that explains all of them. The scan moves. The muscle does not.

Check the vial

The grade above describes a molecule studied under controlled conditions. It says nothing about the powder in a particular vial.

That gap is the one part of this market a reader can actually close. How to read a certificate of analysis covers the five measures in five minutes, and the 2026 audit grades vendors on the documents they publish against a rubric printed in full.

Questions we get

What is MOTS-c used for?

On the human record, nothing yet. It is sold for fat loss, metabolic health and training energy. The support is mouse work: MOTS-c prevented diet-induced obesity and insulin resistance ¹ and improved physical performance in young, middle-aged and old mice ².

The first human trial, a phase 2 in 120 adults with prediabetes, is still recruiting and has posted no results ⁶.

How is MOTS-c used?

Descriptively, and not as guidance: subcutaneous injection from a reconstituted vial, either daily for a short block or several times a week around training. That pattern comes from forums, not from a study.

No human dose has been published, and the registered phase 2 has not posted its schedule ⁶. The mouse work dosed by injection over weeks ¹².

How long does MOTS-c take to work?

No trial has measured that, in any population. Community reports describe training energy inside the first week and, in the same threads, no change at five weeks. Neither is an outcome measurement.

The registered phase 2 will read insulin sensitivity at 12 weeks, which is the first real answer this question will get ⁶.

Does MOTS-c have a human trial?

One, and it has no results. A phase 2 in 120 adults with prediabetes and overweight or obesity is recruiting, measuring the Matsuda index at 12 weeks ⁶.

Nothing has been posted. FDA reviewed MOTS-c for compounding and states it has identified no human exposure data by any route ⁹. A recruiting trial is not a result.

Is MOTS-c an exercise mimetic?

Not on the evidence. Exercise raises the body's own MOTS-c in human skeletal muscle and in circulation, which is the observation the phrase comes from ².

No study has tested injected MOTS-c against training, in any species. The mouse results are about what injected peptide did to mice, not about what it replaces in a person.

References

Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21:443-454. PMID 25738459
Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470. PMID 33473109
Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity. Aging Cell. 2015;14:921-923. PMID 26289118
Du C, Zhang C, Wu W, et al. Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatr Diabetes. 2018. PMID 29691953
Qin Q, Delrio S, Wan J, et al. Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. Int J Cardiol. 2018;254:23-27. PMID 29242099
ClinicalTrials.gov. MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight/obesity, NCT07505745. Phase 2, 120 participants, recruiting. Accessed 24 Aug 2026. clinicaltrials.gov
Ozkaya DY, Ozgen Saydam B, Cetinkalp S, et al. MOTS-c levels in individuals with and without obesity and its association with inflammation, insulin resistance and endothelial dysfunction. Arch Endocrinol Metab. 2025;69:e250063. PMID 41004666
Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28:516-524. PMID 29983246
US Food and Drug Administration. Certain bulk drug substances for use in compounding may present significant safety risks. Accessed 24 Aug 2026. fda.gov
Musolino M, Presta P, Cianfrone P, et al. MOTS-c is associated with oxidative stress and arterial stiffness in peritoneal dialysis patients: a pilot study. Int Urol Nephrol. 2026. PMID 42126770

Inside Your Peptides is published by the owners of the next lab, a vendor graded elsewhere on this site. We sell nothing here, and this page carries no vendor link. Grades follow the published criteria in our editorial policy — never referral terms. Research and education only. Not medical advice.